Cover Image
Market Research Report

Global Anti-malarial Medicines Market 2018-2022

Published by TechNavio (Infiniti Research Ltd.) Product code 711705
Published Content info 117 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Anti-malarial Medicines Market 2018-2022
Published: September 21, 2018 Content info: 117 Pages
Description

About Malaria

Malaria is a life-threatening disease caused by parasites which are transmitted to people through the bite of an infected female anopheles mosquitoes. This disease is preventable and curable. Humans are infected by four recognized species of malarial parasites, namely, Plasmodium falciparum, P. vivax, P. ovale, and P. malariae.

Technavio's analysts forecast the Global Anti-malarial Medicines Market to grow at a CAGR of 4.76% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the anti-malarial medicines market. To calculate the market size, the report considers the revenue generated by sales of anti-malarial drugs across the globe.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Anti-malarial Medicines Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • Sun Pharmaceutical Industries

Market driver

  • Strong funding to eradicate malaria
  • For a full, detailed list, view our report

Market challenge

  • Drug resistant pathogens
  • For a full, detailed list, view our report

Market trend

  • Enhancement of POC diagnostics and biomarkers for malaria
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR23769

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: PIPELINE

PART 08: MARKET SEGMENTATION BY PRODUCT

  • Segmentation by product
  • Comparison by product
  • Artemisinin compounds - Market size and forecast 2017-2022
  • Quinolines and related compounds - Market size and forecast 2017-2022
  • Other compounds - Market size and forecast 2017-2022
  • Market opportunity by product

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • Sun Pharmaceutical Industries

PART 16: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market
  • Exhibit 02: Global infectious disease medicines market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2017
  • Exhibit 07: Validation techniques employed for market sizing 2017
  • Exhibit 08: Global anti-malarial medicines market - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 09: Global anti-malarial medicines market - Year-over-year growth 2018-2022 (%)
  • Exhibit 10: Five forces analysis 2017
  • Exhibit 11: Five forces analysis 2022
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2017
  • Exhibit 18: Pipeline landscape by development phase 2017-2018
  • Exhibit 19: Pipeline molecules for the treatment of malaria 2017-2018
  • Exhibit 20: Global anti-malarial medicines market by product - Market share 2017-2022 (%)
  • Exhibit 21: Comparison by product
  • Exhibit 22: Artemisinin compounds - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 23: Global anti-malarial medicines market by artemisinin compounds - Year-over-year growth 2018-2022 (%)
  • Exhibit 24: Global anti-malarial medicines market by quinolines and related compounds - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 25: Global anti-malarial medicines market by quinolines and related compounds - Year-over-year growth 2018-2022 (%)
  • Exhibit 26: Global anti-malarial medicines market by other compounds - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 27: Global anti-malarial medicines market by other compounds - Year-over-year growth 2018-2022 (%)
  • Exhibit 28: Market opportunity by product
  • Exhibit 29: Customer landscape
  • Exhibit 30: Global anti-malarial medicines market by geography - Market share 2017-2022 (%)
  • Exhibit 31: Regional comparison
  • Exhibit 32: Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 33: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 34: Top 3 countries in Americas
  • Exhibit 35: EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 36: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 37: Top 3 countries in EMEA
  • Exhibit 38: APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 39: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 40: Top 3 countries in APAC
  • Exhibit 41: Market opportunity
  • Exhibit 42: Percentage of people at risk of malaria worldwide
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: F. Hoffmann-La Roche: Overview
  • Exhibit 49: F. Hoffmann-La Roche - Business segments
  • Exhibit 50: F. Hoffmann-La Roche - Organizational developments
  • Exhibit 51: F. Hoffmann-La Roche - Geographic focus
  • Exhibit 52: F. Hoffmann-La Roche - Segment focus
  • Exhibit 53: F. Hoffmann-La Roche - Key offerings
  • Exhibit 54: F. Hoffmann-La Roche - Key customers
  • Exhibit 55: GlaxoSmithKline: Overview
  • Exhibit 56: GlaxoSmithKline - Business segments
  • Exhibit 57: GlaxoSmithKline - Organizational developments
  • Exhibit 58: GlaxoSmithKline - Geographic focus
  • Exhibit 59: GlaxoSmithKline - Segment focus
  • Exhibit 60: GlaxoSmithKline - Key offerings
  • Exhibit 61: GlaxoSmithKline - Key customers
  • Exhibit 62: Novartis: Overview
  • Exhibit 63: Novartis - Business segments
  • Exhibit 64: Novartis - Organizational developments
  • Exhibit 65: Novartis - Geographic focus
  • Exhibit 66: Novartis - Segment focus
  • Exhibit 67: Novartis - Key offerings
  • Exhibit 68: Novartis - Key customers
  • Exhibit 69: Pfizer: Overview
  • Exhibit 70: Pfizer - Business segments
  • Exhibit 71: Pfizer - Organizational developments
  • Exhibit 72: Pfizer - Geographic focus
  • Exhibit 73: Pfizer - Segment focus
  • Exhibit 74: Pfizer - Key offerings
  • Exhibit 75: Pfizer - Key customers
  • Exhibit 76: Sun Pharmaceutical Industries: Overview
  • Exhibit 77: Sun Pharmaceutical Industries - Business segments
  • Exhibit 78: Sun Pharmaceutical Industries - Organizational developments
  • Exhibit 79: Sun Pharmaceutical Industries - Geographic focus
  • Exhibit 80: Sun Pharmaceutical Industries - Segment focus
  • Exhibit 81: Sun Pharmaceutical Industries - Key offerings
  • Exhibit 82: Sun Pharmaceutical Industries - Key customers
Back to Top